Gilead Sciences (GILD) Finished Goods (2009 - 2015)
Gilead Sciences' (GILD) quarterly Finished Goods came in at $852.0 million in Q4 2015, up 82.83% YoY from $466.0 million in Q4 2014, and up 82.83% on a QoQ basis from $466.0 million in Q4 2014.
Gilead Sciences (GILD) Finished Goods (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has 7 years of Finished Goods data on file, last reported at $852.0 million in Q4 2015.
- Quarterly Finished Goods rose 82.83% year-over-year to $852.0 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $852.0 million (up 82.83% YoY) and the FY2015 annual result came in at $852.0 million, up 82.83% from the prior year.
- Finished Goods climbed to $852.0 million in Q4 2015, from $466.0 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $852.0 million in Q4 2015 to a low of $225.9 million in Q4 2011.
- A 5-year average of $487.3 million and a median of $466.0 million in 2014 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2011 — Finished Goods sank 33.79% — and 2012, when it jumped 147.9%.
- Tracing GILD's Finished Goods over 5 years: stood at $225.9 million in 2011, then jumped by 147.9% to $559.9 million in 2012, then increased by 5.99% to $593.4 million in 2013, then retreated by 21.47% to $466.0 million in 2014, then soared by 82.83% to $852.0 million in 2015.
- The last three Finished Goods figures came in at $852.0 million (Q4 2015), $466.0 million (Q4 2014), and $560.0 million (Q2 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 852.00 Mn |
| Dec 31, 2014 | 466.00 Mn |
| Jun 30, 2014 | 559.98 Mn |
| Dec 31, 2013 | 593.44 Mn |
| Dec 31, 2012 | 559.91 Mn |
| Dec 31, 2011 | 225.86 Mn |
| Sep 30, 2011 | 295.79 Mn |
| Jun 30, 2011 | 384.72 Mn |
| Mar 31, 2011 | 448.43 Mn |
| Dec 31, 2010 | 341.14 Mn |
| Sep 30, 2010 | 439.32 Mn |
| Dec 31, 2009 | 326.15 Mn |